Sponsored content from i2i Marketing Group, LLC Dear Reader, Gold didn't just trend higher in 2025 - it reshaped expectations. After years of debate, the metal reclaimed its place as a serious macro asset, pulling capital back into the sector and resetting long-term forecasts. Now, major banks are looking ahead. JPMorgan expects gold demand to remain strong through 2026 and beyond, with prices pushing much higher as supply constraints and global uncertainty persist. When outlooks stretch that far forward, the market doesn't just focus on price - it starts looking for leverage. That's where early-stage gold stories come into view. One company, in particular, is starting to stand out. It controls a large, multi-million-ounce gold project in a proven jurisdiction - and it's being built by a team that has taken major gold assets to much larger outcomes in the past. The scale is already defined. The ambition hasn't stopped there. Despite that, it is still being treated like an early-stage company. Shares remain priced under $2, even as long-term plans and positioning begin to align with a much stronger gold backdrop. This is the phase most investors miss. It's before broad coverage, before consensus, and before valuation catches up to potential. But it's often when the risk-reward is most asymmetric. If gold's next phase plays out the way major institutions expect, stories like this don't stay quiet for long.
Thursday's Featured Article Is Abbott's January Pullback a Good Time to Buy? By Thomas Hughes. Posted: 1/22/2026. The odds are high that Abbott Laboratories' (NYSE: ABT) January 2026 pullback is not just a good buying opportunity but a particularly attractive one. The decline appears driven more by market angst than by company weakness — a knee-jerk overreaction that returns the stock to a buying zone. That zone corresponds to the 2022–2024 price range, when Abbott was recovering from its post‑COVID-19 revenue contraction and institutions were accumulating shares. 
Article Highlights - Abbott Laboratories' January price implosion is a buying opportunity of monumental proportions.
- Driven by tepid performance, this Dividend King is growing its business and its dividend.
- Analysts noted concern but maintained a Moderate Buy rating, highlighting the deep-value opportunity.
Abbott Laboratories Growth Accelerates The most you can say about Abbott Laboratories' Q4 results and guidance is that a few metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings grew at an accelerated pace. In short, revenue growth lagged by several hundred basis points, but margin strength and operational gains helped push adjusted EPS up about 12%, slightly above consensus. Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund.
It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you."
This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. Click here for the full story. By segment, results show the benefits of Abbott’s diversified healthcare portfolio. Nutrition and Diagnostics contracted (Nutrition fell nearly 9%), but gains in Established Pharmaceuticals and Med Tech offset those declines. The pharma segment grew 9.0%, driven by generics and emerging markets, while Med Tech rose 12.3%, with strength across its subsegments. Margin performance was also encouraging, even if it missed some analyst forecasts. A shift in product mix, strength in Med Tech, reduced COVID-19 sales and operational improvements together left margins ahead of expectations. Management expects that improvement to continue, forecasting earnings growth of roughly 10% in 2026 — above revenue growth — which should support the company’s capital-return plans. Abbott’s capital returns are a central part of the investment case. The company is a Dividend Aristocrat, having raised its payout annually for more than 50 years, and it appears positioned to continue that trend. After the pullback the stock yields about 2.5%, and the company pays out less than 50% of consensus earnings estimates, leaving room in cash flow for share buybacks, which help offset the impact of dilutive equity compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts flagged the revenue miss, but no major rating or price-target cuts were issued the morning after the release. The prevailing view is that this fundamentally healthy company can continue returning capital while reinvesting in growth, and the longer-term outlook is substantial. The consensus price target reported by MarketBeat implies upside of as much as 30%, potentially setting new all-time highs; even the lowest targets suggest some upside. Key catalysts include expansion of the Med Tech portfolio, AI integration across operations and products, margin expansion, and acquisitions. The proposed acquisition of Exact Sciences is one example of how Abbott is broadening its revenue and profit streams as well as its product pipeline. The decline in Abbott’s share price has been sharp and could deepen. However, institutions were net buyers throughout 2025 and are likely buyers again at these discounted levels. Early indications show tentative support in the $105 to $110 range, though it is not yet confirmed. The main risk is that ABT shares fall to the low end of the buy zone before recovering — possibly toward $95 or lower — before a rebound ensues.
| 
